Page Banner

United States Department of Agriculture

Agricultural Research Service

You are here: ARS Home / Collaborating / Office of Technology Transfer / Animal Health
Animal Health
headline bar

Each year, approximately 60 new patents are issued by the U.S. Patent Office for USDA inventions. The Office of Technology Transfer (OTT) transfers these inventions through licenses to the private sector for commercialization. Below are links to technologies that are available for licensing. Please contact OTT licensing staff for more information on a specific invention.

Subject Matter

Docket

Title

Description

Animal Health

154.1

REAGENTS TO DETECT GIARDIA LAMBLIA TROPHOZOITES AND CYSTS

Antisera were prepared in rabbits using recombinant proteins expressed in Escherichia coli.  While antisera provides a high titer reagent to detect G. lamblia cysts and trophozoites, monoclonal antibodies could also be prepared that recognize these giardin proteins. These could provide an unlimited supply of detection reagent without the need to repeatedly immunize animals to obtain antisera.

Animal Health

51.11

USE OF VITAMIN D IN DAIRY MASTITIS TREATMENT

The hydroxylated derivates of vitamins D3 or D2 are administered to the mammary gland of a female animal in an amount effective to inhibit or significantly reduce the growth of bacteria in the animal's mammary gland.

Animal Health

128.10

NEW METHOD AND DEVICE FOR SCRUBBING AMMONIA FROM AIR EXHAUSTED FROM ANIMAL REARING FACILITIES USING POTASSIUM BISULFATE AS THE ACID SOURCE

The containment facility ventilation system comprises a two stage scrubber configuration.  Exhaust air flows out of an animal containment facility and into a particulate scrubber, which removes particulates, reduces the dust and alkalinity of the exhaust air.  The air then flows into a chemical scrubber which removes ammonia from the exhaust air.  The chemical scrubber comprises a potassium bisulfate scrubber solution.  The bioproducts create a potential fertilizer.

Animal Health

69.08

HIGH ENERGY ELECTRON-BEAM IRRADIATION FOR THE PRODUCTION OF IMMUNOMODULATORS IN POULTRY

Invention to produce effective vaccines utilizing High Energy (10 MeV) Electron-Beam (E-beam) Irradiation offers unique and effective methodologies to produce large volumes of vaccines including viruses, bacteria, and protozoal candidates.  The stated invention relies on using high energy ionizing radiation to "kill" the target microorganism without destroying their immunogenicity (i.e., capacity to elicit an immune response).

Animal Health

105.10

INACTIVATED VIBRIO VULNIFICUS VACCINE

Vibrio vulnificus is a Gram-negative halophilic bacterium common to estuarine and marine environments.  The bacterium receives much attention due to the ability to produce disease in humans (usually immunocompromised people) either by consumption of raw oysters and/or contact with the bacterium in the marine environment.  The USDA isolated and characterized V. vulnificus from the sick fish. Biochemical analyses demonstrated that the isolate is a biotype 1 isolate and molecular characterization of the 16S rRNA demonstrated the isolate was 16S rRNA type B.  This rRNA type is usually associated with clinical human cases.  Following isolation and characterization, ARS developed an inactivated vaccine that is effective in preventing the disease in tilapia grown in low saline water (1.5 ppt). 

Animal Health

161.03

IMMUNOPOTENTIATING EFFECT OF A FOMITELLA FRAXINEA DERIVED LECTIN OF CHICKEN IMMUNITY AND RESISTANCE TO COCCIDIOSIS

This invention reports a novel immunopotentiating effect of a lectin (FFrL) extracted from the mushroom Fomitella fraxinea on poultry intestinal immunity and poultry coccidiosis.  The treatment regimen could involve oral feeding, intramuscular injection or intravenous injection.

Animal Health

8.08

MODIFIED ASPERGILLUS NIGER PHYTASE

The invention relates to the modification of Aspergillus niger phytase PhyA to produce an enzyme with superior heat tolerance.  For swine and poultry.

Animal Health

115.07

MAREK'S DISEASE VIRUS VACCINE

An effective vaccine for Marek's disease may be prepared using a viral agent which is a Marek’s disease virus unable to express a functional meq protein. 

Animal Health

28.08 + 12.11 + 217.13

HYBRIDOMAS PRODUCING HIGHLY SPECIFIC MONOCLONAL ANTIBODIES TO DETECT MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS

Hybridoma cell lines which produce and secrete monoclonal antibodies which selectively bind to Mycobacterium avium subspecies paratuberculosis have been produced.  Cells of M. avium subspecies paratuberculosis in biological samples may be detected and d quantified by contacting the sample with the antibodies to form a M. avium subspecies paratuberculosis/antibody immunocomplex when M. avium subspecies paratuberculosis is present, which immunocomplex may then be detected. Hybridoma cell lines which produce and secrete monoclonal antibodies which selectively bind to Mycobacterium avium subspecies paratuberculosis have been produced.

Animal Health

105.09

METHOD FOR FLOCCULANTING SUSPENSION USING BIOBASED RENEWABLE FLOCCULANTS

Methods for producing flocculants from chicken blood. 

Animal Health

70.10

PRODUCTION OF ANTI-PEPTIDE MONOCLONAL ANTIBODIES TO DISTINGUISH
EXOTIC NEW CASTLE DISEASES VIRUS FROM VACCINE STRAINS OF NEWCASTLE DISEASE VIRUS

Anti-peptide monoclonal antibodies(MAb's) specific for Exotic Newcastle Disease (END) are used for rapid diagnostic identification between poultry infected with vaccine strains of NDV (LaSota/B1) and END virus (ENDV).

Animal Health

161.12

RECOMBINANT MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS PROTEINS INDUCE IMMUNITY AND PROTECT AGAINST INFECTION

The invention is a vaccine for paratuberculosis (Johne’s Disease) comprised of Mycobacterium avium subsp. paratuberculosis (MAP) proteins.  Induction of the immune response significantly reduces or eliminates colonization of the animal by MAP, and consequently reduces or eliminates fecal shedding of MAP.  Vaccination with the compositions provides protection against clinical disease and reduce transmission of MAP infection within a herd.

Animal Health

87.10 + 10.14

ATTENUATED LIVE VACCINES FOR AQUATIC ANIMALS

Safe and effective live vaccines against bacteria infecting aquatic animals developed by the induction of novobiocin-resistance in liquid culture and novobiocin-and rifampicin-resistance in liquid culture.

Animal Health

23.08

AVIAN VIRUS VACCINES AND USES THEREOF

The invention relates to poultry vaccines for protection from Newcastle Disease.

Animal Health

186.11

HIGH AFFINITY MONOCLONAL ANTIBODIES FOR DETECTION OF SHIGA TOXIN 2 (STX2)

High affinity monoclonal antibodies against Shiga toxin strain Stx2 and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting Stx2 and variants thereof in a sample.

Animal Health (Prion)

78.06

NOVEL POLYMORPHISM IN BOVINE PRION PROTEIN GENE SEQUENCE

A specific, non-synonymous SNP in the Prnp gene encoding the bovine prion protein affects the susceptibility of bovine animals to bovine spongiform encephalopathy (BSE). 

Animal Health (Prion)

30.11

NOVEL POLYMORPHISM IN BOVINE PRION PROTEIN GENE SEQUENCE

This SNP may be used as a marker for selecting bovines susceptible to BSE for disposal and/or removal from breeding, the human food and animal feed supplies.

Animal Health (Prion)

131.07

PEPTIDE SEQUENCES FOR BINDING INFECTIOUS PRIONS

The invention relates to novel peptide sequences that specifically bind infectious prion protein.

Animal Health (Prion)

144.09 + 181.13

HIGH-AFFINITY MONOCLONAL ANTI-PRION ANTIBODIES

Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents.

 


Last Modified: 5/29/2014
Footer Content Back to Top of Page